CVE-2025-0416
Valmet DNA Local privilege escalation through insecure DCOM configuration
Local privilege escalation through insecure DCOM configuration in Valmet DNA versions prior to C2023. The DCOM object Valmet DNA Engineering has permissions that allow it to run commands as a user with the SeImpersonatePrivilege privilege. The SeImpersonatePrivilege privilege is a Windows permission that allows a process to impersonate another user. An attacker can use this vulnerability to escalate their privileges and take complete control of the system.
Attack profile
How easy it is to exploit
- Attack vector
- Adjacent network
- Complexity
- Low
- Privileges needed
- Low
- User interaction
- None
What an attacker can affect
- Confidentiality
- High
- Integrity
- High
- Availability
- High
Exploit likelihood
What each source reports
CVE List Score used
8.9
Valmet DNA Local privilege escalation through insecure DCOM configuration
Local privilege escalation through insecure DCOM configuration in Valmet DNA versions prior to C2023. The DCOM object Valmet DNA Engineering has permissions that allow it to run commands as a user with the SeImpersonatePrivilege privilege. The SeImpersonatePrivilege privilege is a Windows permission that allows a process to impersonate another user. An attacker can use this vulnerability to escalate their privileges and take complete control of the system.
- Record
CVE-2025-0416- CVSS 4.0
- 8.9 High
CVSS:4.0/AV:A/AC:L/AT:P/PR:L/UI:N/VC:H/VI:H/VA:H/SC:H/SI:H/SA:H/S:N/AU:Y/R:U/V:D/RE:H/U:Amber - Weakness
- CWE-250
- Updated
- 2026-11-02
EUVDEUVD-2025-9126
8.9
Local privilege escalation through insecure DCOM configuration in Valmet DNA versions prior to C2023. The DCOM object Valmet DNA Engineering has permissions that allow it to run commands as a user with the SeImpersonatePrivilege privilege. The SeImpersonatePrivilege privilege is a Windows permission that allows a process to impersonate another user. An attacker can use this vulnerability to escalate their privileges and take complete control of the system.
- Record
EUVD-2025-9126- CVSS 4.0
- 8.9 High
CVSS:4.0/AV:A/AC:L/AT:P/PR:L/UI:N/VC:H/VI:H/VA:H/SC:H/SI:H/SA:H/S:N/AU:Y/R:U/V:D/RE:H/U:Amber - Updated
- 2026-11-02
GitHub AdvisoriesGHSA-23pg-v644-m29h
8.9
Local privilege escalation through insecure DCOM configuration in Valmet DNA versions prior to...
Local privilege escalation through insecure DCOM configuration in Valmet DNA versions prior to C2023. The DCOM object Valmet DNA Engineering has permissions that allow it to run commands as a user with the SeImpersonatePrivilege privilege. The SeImpersonatePrivilege privilege is a Windows permission that allows a process to impersonate another user. An attacker can use this vulnerability to escalate their privileges and take complete control of the system.
- Record
GHSA-23pg-v644-m29h- CVSS 4.0
- 8.9 High
CVSS:4.0/AV:A/AC:L/AT:P/PR:L/UI:N/VC:H/VI:H/VA:H/SC:H/SI:H/SA:H/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:N/AU:Y/R:U/V:D/RE:H/U:Amber - Weakness
- CWE-269
- Updated
- 2026-11-02
NVD
8.9
Local privilege escalation through insecure DCOM configuration in Valmet DNA versions prior to C2023. The DCOM object Valmet DNA Engineering has permissions that allow it to run commands as a user with the SeImpersonatePrivilege privilege. The SeImpersonatePrivilege privilege is a Windows permission that allows a process to impersonate another user. An attacker can use this vulnerability to escalate their privileges and take complete control of the system.
- Record
CVE-2025-0416- CVSS 4.0
- 8.9 High
CVSS:4.0/AV:A/AC:L/AT:P/PR:L/UI:N/VC:H/VI:H/VA:H/SC:H/SI:H/SA:H/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:N/AU:Y/R:U/V:D/RE:H/U:Amber - Weakness
- CWE-250
- Updated
- 2026-11-02
Affected products
History
| Recorded | Changed | Sources |
|---|---|---|
| first indexed | CVE List, EUVD, GitHub Advisories, NVD |
Dates are when Every CVE recorded each change. Upstream dates may differ.
In short
CVE-2025-0416 is a high vulnerability (CVSS 8.9) in Valmet Dna, published April 1, 2025. No source lists public exploit code. EPSS puts the chance of exploitation in the next 30 days at 0.21%, the 11th percentile. No source names a fixed version.